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Introduction
Allogeneic stem cell transplantation (HSCT) is currently the
standard therapy for many hematologic disorders and its use
has markedly increased over the past two decades. Graft-ver-
sus-host disease (GVHD), infections and relapse are the most
common complications of allogeneic HSCT. Recent studies
have begun to recognize that allogeneic HSCT recipients are
also prone to the complications of a higher rate of throm-
boembolic events (TEEs) including venous thromboembolism
(VTE)1,2 and arterial events (ischemic stroke, coronary artery
disease (CAD) or peripheral artery disease).3,4 In two recent
studies, the 1-year incidences of allogeneic stem cell trans-
plantation-associated VTE were 2.5% and 4.6%.5,6 The cumu-
lative incidence of arterial events 15 years after allogeneic
HSCT was 6%.4 Factors that have been suggested to increase
the risk of VTE in HSCT recipients include indwelling central
venous catheters, development of GVHD, and previous VTE.6
In addition, the occurrence of arterial thrombotic events was
significantly higher in HSCT recipients with at least two car-
diovascular risk factors.4
However, the risk of TEEs in HSCT recipients should be
balanced with the risk of hemorrhagic complications.
Bleeding is also a highly significant complication of allogeneic
HSCT and has been associated with shorter survival.7-9
Prolonged thrombocytopenia and HSCT-specific hemorrhag-
ic complications, such as hemorrhagic cystitis, diffuse alveolar
hemorrhage, and gastrointestinal GVHD, are strong predic-
tors of bleeding in allogeneic HSCT.10 Therefore, despite the
fact that TEEs occur frequently during the post-transplant
period, VTE prophylaxis is not generally used in allogeneic
HSCT recipients. In addition, except for one study that simul-
taneously evaluated bleeding and thrombotic complications
in early phases of allogeneic HSCT (<128 days),6 little is
known about the competing risks of thrombosis and bleeding
in this complex population. The purpose of this study was to
determine the incidence, risk factors and mortality due to
TEEs and bleeding in a large series of patients who underwent
allogeneic HSCT in a single institution.
Design and Methods
Study subjects
Analyses were performed in accordance with the Declaration of
Helsinki and the guidelines of the institutional review board of the
Hospital Universitario de Salamanca. This study was approved by the
Salamanca University Hospital Ethics Committee. We conducted a
retrospective cohort study of 443 consecutive patients (aged over 18
©2013 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2012.069559
Manuscript received May 4, 2012. Manuscript accepted August 9, 2012.
Correspondence: jrgp@usal.es
Allogeneic hematopoietic stem cell transplantation recipients have an increasing risk of both hemorrhagic and
thrombotic complications. However, the competing risks of two of these life-threatening complications in these
complex patients have still not been well defined. We retrospectively analyzed data from 431 allogeneic transplan-
tation recipients to identify the incidence, risk factors and mortality due to thrombosis and bleeding. Significant
clinical bleeding was more frequent than symptomatic thrombosis. The cumulative incidence of a bleeding
episode was 30.2% at 14 years. The cumulative incidence of a venous or arterial thrombosis at 14 years was
11.8% and 4.1%, respectively. The analysis of competing factors for venous thrombosis revealed extensive chron-
ic graft-versus-host disease to be the only independent prognostic risk factor. By contrast, six factors were associ-
ated with an increased risk of bleeding; advanced disease, ablative conditioning regimen, umbilical cord blood
transplantation, anticoagulation, acute III-IV graft-versus-host disease, and transplant-associated microangiopathy.
The development of thrombosis did not significantly affect overall survival (P=0.856). However, significant clinical
bleeding was associated with inferior survival (P<0.001). In allogeneic hematopoietic stem cell transplantation, sig-
nificant clinical bleeding is more common than thrombotic complications and affects survival.
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years) who had undergone allogeneic HSCT between 1995 and
2011 at the Hospital Universitario de Salamanca. Twelve patients
who received prophylaxis or therapeutic anticoagulation at the
time of HSCT admission were excluded. Informed consent was
obtained from all patients before HSCT. The main demographic
and hematologic features of the 431 evaluable allogeneic HSCT
recipients are shown in Table 1. Median age was 47±13 years;
61% of patients were male. Median follow up was 20 months
(range 1-137 months). The conditioning regimen was myeloabla-
tive (n=193) or reduced-intensity conditioning (RIC) (n=238)
(Table 1). The day of stem cell infusion was designated as Day 0.
Prophylactic platelet transfusion was given when the platelet
count fell below 10x109/L or 10-20x109/L in those with fever
(>38°C). Post-HSCT complications, such as GVHD, vein-occlusive
disease (VOD) and thrombotic microangiopathy (TMA), were
also recorded. GVHD was defined according to the Seattle criteria
for the diagnosis and staging of GVHD.11 VOD was diagnosed
according to the Modified Seattle Criteria.12 A diagnosis of trans-
plant-associated microangiopathy (TMA) was made in patients
with microangiopathic hemolytic anemia, thrombocytopenia,
renal failure and high levels of serum lactate dehydrogenase.13 As
our enrollment period was very long (1995-2011), we have
addressed any possible change in baseline characteristics of
patients over time (1995-2004 vs. 2005-2011). The age of recipients
has significantly increased in the second period (42.3 vs. 47.9,
P<0.001). The number of patients who underwent an unrelated
HSCT increased from 11.7% in the period 1995-2004 to 38.3% in
2005-2011, P<0.001. Also, a higher proportion of patients receiv-
ing non-myeloablative conditioning regimen was also observed in
the 2005-2011 period. 
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Table 1. Baseline characteristics of patients (n=431).
Variable Total (1995 – 2004) (2005 – 2011) P
Years years
Age (median ± SD) 47±13.9 42.3±13.2 47.9±12.4 <0.001
Gender (male / female) (%) 61/39 58.2/41.8 63.4/36.6 0.267
Cardiovascular risk factors
Hypertension 30 (7) 12 (6.1) 18 (7.7) 0.573
Diabetes 18 (4.2) 6 (3.1) 12 (5.1) 0.340
Dyslipemia 27 (6.3) 7 (3.6) 20 (8.5) 0.045
Body mass index (median ± SD) 24.1±3.8 24.1±3.5 25.3±4.1 0.002
Prior VTE 19 (4.4) 10 (5.1) 9 (3.8) 0.639
Diagnosis 0.009
Acute myeloid leukemia 120 (27.8) 48 (24.5) 72 (30.6)
Myelodysplastic syndrome 57 (13.2) 27 (13.8) 30 (12.8)
Non-Hodgkin’s lymphoma 57 (13.2) 16 (8.2) 41 (17.4)
Acute lymphocytic leukemia 56 (13) 28 (14.3) 28 (11.9)
Multiple myeloma 40 (9.3) 21 (10.7) 19 (8.1)
Chronic myeloid leukemia 39 (9) 26 (13.3) 13 (5.5)
Others 62 (14.4) 30 (15.3) 32 (13.6)
Donor < 0.001
Related allogeneic 318 (73.8) 173 (88.3) 145 (61.7)
Unrelated allogeneic 113 (26.2) 23 (11.7) 90 (38.3)
Stage of the disease 0.212
Low risk 209 (48.5) 96 (49) 113 (48.1)
Intermediate risk 134 (31.1) 54 (27.6) 80 (34)   
Advanced risk 88 (20.4) 46 (23.5) 42 (17.9)
Source of stem cell 0.007
Peripheral blood 346 (80.3) 159 (81.1) 187(79.6)
Bone marrow 67 (15.5) 35 (17.9) 32 (15.5)
Umbilical cord 18 (4.2) 2 (1) 16 (6.8)
Conditioning regimen 0.006
RIC 238 (55.2) 94 (48) 144 (61.3)
Myeloablative 193 (44.8) 102 (52) 91 (38.7)
Prophylaxis of GVHD < 0.001
Cyclosporine plus methotrexate 306 (71) 173 (83.2) 135 (60.5)
Tacrolimus plus rapamycin 38 (9) 0 39 (17.5)
Cyclosporine plus mycophenolate mofetil 29 (7) 18 (8.6) 12 (5.4)
Others 62 (12) 10 (4.8) 19 (8.5)
Complications after HSCT
Grade III–IV acute GVHD 52 (12.1) 19 (9.7) 33 (14) 0.184
Extensive chronic GVHD 130 (30.2) 78 (48.1) 52 (27.4) < 0.001
Vein-occlusive disease 26 (6) 24 (12.2) 2 (0.9) < 0.001
Thrombotic microangiopathy 32 (7.4) 20 (10.2) 12 (5.1) 0.064
VTE: venous thromboembolism; stage of disease: low risk (first complete remission or chronic phase), high risk (relapse or progressive disease, blast crisis) and intermediate risk
(all others); RIC: reduced-intensity conditioning; GVHD: graft-versus-host disease; HSCT: hematopoietic stem cell transplantation.
Indwelling central venous catheters 
A central venous catheter (CVC), a triple-lumen catheter or a
double-lumen Hickman was routinely implanted before infusion
of stem cells. No systemic prophylaxis against deep-vein thrombo-
sis was adopted. Each lumen of CVC was washed with 20 mL
normal sterile saline and 5 mL heparinized saline (50 IU/mL)
according to routine clinical practice. The CVC was removed
when the patient was discharged after HSCT whilst the Hickman
line was maintained until the development of complications that
prompted catheter removal.
Outcomes
The primary end points of the study were the incidence, risk
factors and clinical impact of post-allogeneic HSCT TEEs and
hemorrhages. TEEs were subdivided into venous and arterial
types. Venous TEEs were classified as deep venous thrombosis
(DVT), pulmonary embolism (PE) or catheter-related venous
thrombosis. The diagnosis of DVT was considered valid by
venography or compression ultrasonography, according to stan-
dard methods. Pulmonary embolism was only accepted if it was
demonstrated by perfusion lung scan or computerized tomogra-
phy. The diagnosis of catheter-related venous thrombosis was
defined as the partial or total occlusion of a vein into which a CVC
had been inserted, or a DVT confirmed within 30 days of CVC
removal by ultrasonography or phlebography. Arterial TEEs were
classified as coronary artery disease (CAD), ischemic stroke or
peripheral arterial disease, and diagnosed according to standard
objective methods. Any bleeding event after allogeneic HSCT was
included in the analysis, with the exception of mild petechiae. The
number and location of bleeding sites were recorded. Bleeding
was considered a major event if it conditioned a reduction in the
hemoglobin level of at least 20 g/L, transfusion of at least two
blood-pack units, or symptomatic bleeding in a critical area or
organ. Transfusion events due to aplasia post chemotherapy were
not included. Major bleeding was considered to be life-threatening
if it resulted in: fatality, symptomatic intracranial or pulmonary
bleeding, bleeding with a decrease in the hemoglobin level of at
least 50 g/L, or bleeding requiring transfusion of at least four red
blood-cell units or inotropic agents, or if surgery was required. All
other bleeding was considered to be minor.
Statistical analysis
Data were initially included in an Excel (Microsoft) spreadsheet
and a descriptive statistical analysis was performed. Results are
expressed as percentages for categorical variables and as medians
(and standard deviations) for continuous variables. Differences
between groups were evaluated with SPSS 19.0 (SPSS, Chicago,
IL, USA). Separate logistical regressions were performed using the
backward conditional variable selection method to identify risk
factors for the development of TEEs and bleeding. Variables asso-
ciated with TEEs or bleeding in the bivariate analyses were includ-
ed in the multivariate models. Cumulative incidence of vascular
complications was estimated with death without a vascular event
as the competing risk. Overall survival (OS) was defined as the
time elapsed between HSCT Day 0 and death or last follow up,
and calculated by the Kaplan-Meier method. The log rank test was
used to assess differences between groups of patients with or
without thrombosis, or patients with or without bleeding.
Multivariate survival analysis involved developing Cox’s propor-
tional hazards models with stepwise variable selection. All the
parameters that were significant in the univariate analyses were
included in the multivariate analysis. P<0.05 was considered sta-
tistically significant.
Results
Incidence and risk factors of post-allogeneic HSCT
venous TEEs
A total of 26 patients (6.03%) experienced a venous TEE
after their allo-HSCT. The median time from HSC admin-
istration to diagnosis of venous TEEs was 211 days (range
9-4080 days). There were 16 venous TEEs episodes during
1995-2004 and 10 venous TEEs events during the period
2005-2011 (P=0.09). The cumulative incidence of post-
allogeneic HSCT venous TEEs was 11.8% (95% CI: 7.1-
19.6%) at 14 years (Figure 1). Nineteen patients (4.4%)
developed a venous TEE unrelated to a CVC (11 DVTs, 5
DVTs with EP and 3 isolated PEs). Catheter-related venous
thrombosis was present in 7 patients (1.6%).
Anticoagulation therapy consisted of therapeutic low
molecular weight heparin (LMWH) in 17 patients, and
LMWH followed by acenocumarol with a target interna-
tional normalized ratio of 2-3 in 7 patients. LMWH was
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Figure 1. Cumulative incidence of a venous TEE was 3.6% (95% CI:
2.2-5.9%; 256 patients at risk) at 1 year, 4.8% (95% CI: 3.1-7.5%;
104 patients) at 5 years, 8.1% (95% CI: 5.2-12.6%; 37 patients) at
10 years, and 11.8% (95% CI: 7.1-19.6%; 3 patients) at 14 years. 
Table 2. Bivariate analysis of factors influencing venous TEEs.
Variable Odds ratio 95% CI P
Age < 45 years 1.15 (0.51–2.58) 0.720
Male  0.68 (0.38–1.92) 0.720
Advanced disease 0.92 (0.33–2.52) 0.877
Diabetes pre-HSCT 0.00 - 0.998
Hypertension pre-HSCT 0.51 (0.07–3.96) 0.519
Dyslipemia pre-HSCT 0.58 (0.07–4.47) 0.604
BMI > 25 1.69 (0.74–3.88) 0.210
Prior VTE 1.90 (0.41–3.88) 0.408
Ablative conditioning regimen* 0.75 (0.33–1.71) 0.505
Grade III–IV acute GVHD** 0.94 (0.27–3.27) 0.932
Extensive chronic GVHD*** 2.85 (1.20–6.80) 0.018
Occlusive vein disease 1.32 (0.29–5.93) 0.715
Thrombotic microangiopathy 1.04 (0.23 – 4.62) 0.408
TEEs: thromboembolic events; HSCT: hematopoietic stem cell transplantation; BMI:
body mass index; VTE: venous thromboembolism; GVHD: graft-versus-host disease.
*compared with RIC conditioning regimen; **compared with non-acute GVHD;
***compared with non-chronic GVHD.
0 2 4 6 8 10 12 14 16
Years since allo-HSCT
Cu
m
ul
at
iv
e 
in
ci
de
nc
e
0.2
0.18
0.16
0.14
0.12
0.1
0.08
0.06
0.04
0.02
0.0
not prescribed after CVC withdrawal in 2 patients with
catheter-related venous thrombosis. The anticoagulant
treatment was continued as long as it was clinically indi-
cated. One patient with massive PE died. At the time of
analysis, 5 patients (19.2%) had developed one episode of
documented recurrent venous thrombosis. Table 2 shows
the bivariate analysis factors for venous TEEs. The devel-
opment of extensive chronic GVHD was the only risk fac-
tor for the occurrence of venous TEEs post-allogeneic
HSCT (OR 2.85; 95% CI: 1.20-6.80). 
Incidence and risk factors of post-allogeneic HSCT
arterial TEEs
Eleven of the 431 (2.5%) patients had an arterial TEE
after allogeneic HSCT (8 CAD and 3 ischemic strokes).
The cumulative incidence of post-allogeneic HSCT arterial
TEEs was 4.1% (95% CI: 1.8-9.3%) at 14 years (Figure 2).
One patient with CAD and 2 patients with ischemic
stroke were treated with acenocumarol (target INR
between 2 and 3) and the 3 patients with stroke received
antiplatelet agent. Two patients died because of CAD.
Only a trend towards a higher rate of arterial events was
observed for patients with a BMI greater than 25 (OR 2.85;
95% CI: 0.81-12.34; P=0.098). 
Incidence and risk factors of post-allogeneic HSCT
bleeding 
In total, 140 hemorraghic events occurred in 111
patients. The median time until the first bleeding episode
was 60 days (range 2-3,660 days). The cumulative inci-
dence of bleeding in allogeneic HSCT recipients was
30.2% (95% CI: 25.2-36.2%) at 14 years (Figure 3); 26.1%
of bleeding episodes occurred during 1995-2004 and 22%
in 2005-2011 (P=0.741). The majority of patients experi-
enced bleeding at a single site with very few patients
(n=25) bleeding from more than two locations.
Genitourinary bleeding was the most common site for
hemorrhagic complications in allogeneic HSCT recipients
(32%) (Table 3), followed by gastrointestinal bleeding
(22.9%). With respect to severity of hemorrhage, 73 of the
bleeding events (52%) were considered major bleeding
and 44 bleeding episodes (31.4%) were life-threatening
events. The majority of life-threatening bleedings affected
either the lungs (n=16), the gastrointestinal (GI) tract
(n=10) or the central nervous system (CNS) (n=12).
Twenty deaths were directly attributable to bleeding.
Thirty-eight (8.8%) patients developed thrombotic and
bleeding complications. Table 4 shows the univariate and
multivariate analyses carried out to identify the variables
capable of predicting bleeding episodes after allogeneic
HSCT. Advanced disease, ablative conditioning regimen,
use of ATG, umbilical cord transplantation, severe throm-
bocytopenia (platelet count < 20x109/L) after Day + 28,
use of anticoagulation treatment after HSCT, grade III-IV
acute GVHD and TMA were significantly associated with
hemorrhagic complications in the univariate analysis. In
multivariate analyses, six variables retained their associa-
tion with bleeding events: advanced disease, ablative con-
ditioning regimen, umbilical cord blood transplantation,
anticoagulation after HSCT, grade acute III-IV GVHD and
TMA. Interestingly, 10 of 111 patients (9%) had a late
bleeding event (one year after HSCT). In this subgroup of
patients, we analyzed the risk factors for bleeding. The
use of anticoagulant therapy (P=0.003) and severe throm-
bocytopenia after Day 28 (P=0.004) were the risk factors
associated to late bleeding. 
Prognostic impact of bleeding and TEEs following 
allogeneic HSCT
The presence of hemorrhagic complications after HSCT
was associated with an adverse outcome when compared
with patients without bleeding episodes. Median OS of
J. Labrador et al.
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Figure 2. The cumulative incidence of an arterial TEEs was 2.2%
(95% CI: 1.1-4.2%; 256 patients at risk) at 1 year, 2.5% (95% CI: 1.4-
4.7%; 104 patients) at 5 years, and 4.1% (95% CI: 1.8-9.3%; 3
patients) at 14 years. 
Figure 3. The cumulative incidence of a bleeding episode was
21.3% (95% CI: 17.7-25.5%; 237 patients at risk) at 1 year, 26.1%
(95% CI: 22.1-30.8%; 100 patients) at 5 years, 28.9% (95% CI:
24.3-34.4%; 34 patients) at 10 years, and 30.2% (95% CI: 25.2-
36.2%; 3 patients) at 14 years. 
Table 3. Bleeding episodes after HSCT.
Severity of bleeding
Location Number Minor Major
(%) Non-life- Life-
threatening threatening
Genitourinary 45 (32.1%) 28 15 2
Gastrointestinal 32 (22.9%) 14 8 10
Mucosal 18 (12.9%) 14 2 2
Pulmonary 16 (11.4%) – – 16
Central nervous system 12 (8.6%) – – 12
Gynecological 6 (4.3%) 4 2 –
Others 11 (7.8%) 7 2 2
Total 140 (100%) 67 29 44
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patients with bleeding episodes was 15 months, which
was significantly lower than patients without bleeding
episodes (Kaplan-Meier estimate 122 months; log rank test
P<0.001) (Figure 4). In the multivariate analysis, bleeding
events after allogeneic HSCT retained their independent
prognostic influence (HR 3.34; 95% CI: 2.44-4.58) (Table
5). TMA was the strongest determinant of bleeding in our
series and patients who developed TMA had a significant-
ly shorter survival (log rank test P<0.001). But when TMA
was included in the multivariate model, it did not remain
an independent prognostic factor as it was superseded by
the negative prognostic effect of grade III-IV acute GVHD.
No statistical differences were identified in overall survival
between patients with early and late bleeding events.
Finally, there was no significant difference in OS between
allogeneic HSCT recipients with or without TEEs (Kaplan-
Meier estimate; log rank test P=0.856) (Figure 5).
Discussion
In recent years, it has begun to be recognized that the
incidence of TEEs in patients who have undergone allo-
geneic HSCT is similar to that observed in patients with
solid tumors.14 In this setting, a thromboprophylaxis strat-
egy could be effective in preventing TEEs in selected allo-
geneic HSCT recipients. However, TEEs have been sepa-
rately analyzed without taking into consideration the
increasing risk of bleeding in allogeneic HSCT recipients.
Here, we report the largest study to date of the competing
risks of thrombosis and bleeding in allogeneic HSCT. Our
results showed that the cumulative incidence of bleeding
complications was higher than TEE. In addition, hemor-
rhagic complications were of significant independent
prognostic value for OS on multivariate analysis, while
TEE events were not.
In our series, the cumulative incidence of venous TEEs
at 14 years was 11.8%. Similar incidences (3.7-14.6%)
have been reported in other studies.2,5,6 Interestingly, 11 of
26 symptomatic VTE episodes occurred after one year of
allogeneic HSCT. This indicates that allogeneic HSCT
recipients have a similar risk of VTE in the early and late
post-HSCT periods. In our series, the development of
extensive chronic GVHD was the most important predic-
tor of VTE, which is in agreement with two other stud-
ies.6,15 Pihusch et al. confirmed a higher incidence of VTE in
patients with chronic GVHD2 with a limited follow up (<1
Thrombotic and hemorrhagic complications after allogeneic HSCT
haematologica | 2013; 98(3) 441
Figure 4. Overall survival of patients with and without bleeding after
allogeneic HSCT.
Table 4. Univariate and multivariate analysis of factors influencing
bleeding episodes.
Variable Univariate Multivariate Odds
P P Ratio
(95% CI)
Age < 45 years 0.109 0.823 0.93 
(0.53–1.63)
Male 0.952 0.882 0.96 
(0.59–1.55)
Advanced disease 0.046 0.033 1.83 
(1.04–3.21)
Ablative conditioning regimen 0.007 0.018 2.02 
(1.13–3.61)
Use of ATG 0.012 0.693 –
Umbilical cord transplantation * <0.0001 0.027 3.53 
(1.15–10.79)
Severe thrombocytopenia after Day 28 0.002 0.237 –
Anticoagulation after HSCT 0.026 0.009 2.75
(1.29–5.86)
Grade III–IV acute GVHD **  0.002 0.017 2.23 
(1.15–4.32)
Extensive chronic GVHD *** 0.116 – –
Occlusive vein disease 0.547 – –
Thrombotic microangiopathy <0.0001 <0.0001 3.44
(1.54–7.66)
ATG: antithymocyte globulin; HSCT: hematopoietic stem cell transplantation; severe
thrombocytopenia when platelet count <20x109/L; GVHD: graft-versus-host disease.
*Compared with bone marrow stem cells; **compared with non-acute; GVHD; com-
pared with non-chronic GVHD. 
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Figure 5. Overall survival of patients with and without thrombosis
after allogeneic HSCT. 
year). We have identified that the risk of VTE in GVHD
was due to the development of extensive chronic GVHD.
As chronic GVHD can occur for several years after HSCT,
the risk of VTE would remain more than one year of allo-
geneic HSCT. VTE prophylaxis may be useful in extensive
chronic GVHD. However, well-designed clinical trials to
evaluate the risks and benefits of VTE prophylaxis in this
population are needed. Over recent years, we have
observed an increase in the median age of allogeneic trans-
plant patients with the introduction of RIC regimens. An
increase in unrelated and cord blood transplants has also
been observed. These trends observed in our center are
quite similar to those reported by the EBMT registry.16
However, our rate of bleeding/thrombotic complications
has not changed over time. 
The mechanism of thrombogenesis in allogeneic HSCT
recipients who develop GVHD is uncertain. Release of
cytokines involved in the pathophysiology of GVHD may
be associated with a higher risk of VTE. Necrosis factor-
alpha can modulate the endothelial hemostatic function
by increasing levels of prothrombotic plasminogen activa-
tor inhibitor I or tissue factor and by decreasing those of
antithrombotic factors, such as the tissue factor pathway
inhibitor.2 Increasing circulating microparticles released
after intensive cell activation2 could also contribute to the
higher risk of VTE in GVHD.
The development of arterial thrombosis after HSCT has
been of increasing concern during recent years. We found
a cumulative incidence of arterial TEEs of 4.1% at 14
years. This is coincidental with two recent studies in
which allogeneic HSCT recipients had a higher risk of pre-
mature arterial vascular disease.3,4 In these studies, the
presence of cardiovascular risk factors was associated with
higher incidences of arterial thrombosis. We found a trend
towards developing arterial events in subjects with a BMI
over 25. 
This study illustrates that, although thrombosis is a sig-
nificant problem in patients with allogeneic HSCT, it is
not associated with increased mortality. In line with these
results, patients on AML17 or with MM treated with
lenalidomide18 who developed a VTE did not have shorter
overall survival. In contrast, the development of thrombo-
sis in solid tumors is associated with increased mortality.19
In solid tumors, the development of venous thromboem-
bolism suggests the presence of aggressive disease. A
hypercoagulable state induced by tissue factor can be cru-
cial for metastasis.20 However, in allogeneic HSCT the
hypercoagulable state would not be an important factor
influencing aggressiveness.
Bleeding was more frequent than clinical thrombosis
and was associated with increased mortality. However,
we should take into account a possible limitation to our
study since it is likely that thrombosis was not always
detected (subclinical or asymptomatic), and that bleeding
could be over-estimated (although we have tried to
exclude transfusions due to pancytopenia).
The risk of death is higher in allogeneic HSCTs with
symptomatic bleeding than in those without bleeding.
The cumulative incidence of bleeding in our study is quite
similar to that found by other authors.6,7,9 Recent data sug-
gest that the excess bleeding risk after allogeneic HSCT is
restricted to patients developing GVHD, and that patients
without GVHD are not at increased risk of bleeding.2 We
have clarified that severe acute GVHD is responsible for
increased risk of bleeding. Cumulative endothelial and
epithelial damage through immunological injury to the
vasculature could explain the risk of bleeding in GVHD.21
We found that symptomatic bleeding can also occur in sit-
uations other than acute GVHD, such as thrombotic
microangiopathy. Also, situations involving a pancy-
topenic period as a more intense myeloablative condition-
ing, and umbilical cord stem cell transplantation were pre-
dictors of bleeding. 
In conclusion, in this study, which has the longest fol-
low up to date of patients undergoing allogeneic HSCT,
the incidence of VTE was relatively high during early and
late phases of HSCT, but did not influence survival.
Extensive chronic HSCT was the most important risk fac-
tor. In contrast, bleeding was more frequently associated
with increased mortality. The principal risk factors for
bleeding are myeloablative conditioning, umbilical cord
blood transplantation, severe thrombocytopenia after Day
28 and development of grade III-IV acute GVHD or TMA. 
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Table 5. Multivariate analysis of factors influencing overall survival.
Variable                                                              P-Univariate                       Hazard ratio 95% CI P
Age, <45 years                                                                       0.950                                           0.76 (0.57–1.03) 0.078
Male                                                                                         0.026                                           0.90 (0.67–1.20) 0.460
Bleeding                                                                                 0.000                                           3.34 (2.44–4.58) 0.000
Advanced disease                                                                 0.000                                           1.85 (1.34–2.54) 0.000
Ablative conditioning regimen                                          0.560                                             - - -
Use of ATG                                                                             0.179                                             - - -
Stem cell umbilical cord                                                    0.002                                           2.31 (1.28–4.17) 0.000
Severe thrombocytopenia after Day 28                          0.067                                             - - -
Anticoagulation after HSCT                                               0.396                                             - - -
Grade III–IV acute GVHD                                                   0.000                                           1.98 (1.36–2.87) 0.000
Extensive chronic GVHD                                                    0.067                                             - - -
Occlusive vein disease                                                       0.014                                           1.69 (1.05–2.72) 0.031
Thrombotic microangiopathy                                            0.003                                           1.38 (0.86–2.22) 0.185
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